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Abstract
Background: Research into the etiology of breast cancer has recently focused on the role of the immunity and
inflammation. The proinflammatory cytokines IL-17A and IL-17F can mediate inflammation and cancer. To evaluate the
influences of IL-17A and IL-17F gene polymorphisms on the risk of sporadic breast cancer, a case-control study was
conducted in Chinese Han women.
Methodology and Principal Findings: We genotyped three single-nucleotide polymorphisms (SNPs) in IL-17A (rs2275913,
rs3819025 and rs3748067) and five SNPs in IL-17F (rs7771511, rs9382084, rs12203582, rs1266828 and rs763780) to
determine the haplotypes in 491 women with breast cancer and 502 healthy individuals. The genotypes were determined
using the SNaPshot technique. The differences in the genotypic distribution between breast cancer patients and healthy
controls were analyzed with the Chi-square test for trends. For rs2275913 in IL-17A, the frequency of the AA genotype was
higher in patients than controls (P=0.0016). The clinical features analysis demonstrated significant associations between IL-
17 SNPs and tumor protein 53 (P53), progesterone receptor (PR), human epidermal growth factor receptor 2 (Her-2) and
triple-negative (ER-/PR-/Her-2-) status. In addition, the haplotype analysis indicated that the frequency of the haplotype
Ars2275913Grs3819025Grs3748067, located in the IL-17A linkage disequilibrium (LD) block, was higher in patients than in controls
(P=0.0471 after correction for multiple testing).
Conclusions and Significance: Our results suggested that SNPs in IL-17A but not IL-17F were associated with the risk of
breast cancer. Both IL-17A and IL-17F gene polymorphisms may provide valuable information for predicting the prognosis
of breast cancer in Chinese women.
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Introduction
Breast cancer is the most common malignancy in women
worldwide and its rate is increasing in both developed and
developing countries [1]. The etiology of breast cancer is
complicated and not completely understood, but recent studies
have focused on the roles of immunity and inflammation [2].
Th17 cells have recently been identified as a new subset of T
helper cells, in addition to the traditional Th1 and Th2 subsets.
Th17 cells are generally important mediators of inflammation [3],
autoimmune diseases [4] and cancer [5,6], particularly through
the production of IL-17A and IL-17F.
IL-17 is a novel family of proinflammatory cytokines that
consists of six similar members, designated IL-17A (also previously
known as IL-17), IL-17B, IL-17C, IL-17D, IL-17E and IL-17F,
according to the order in which they were discovered [7]. IL-17A
and IL-17F lie immediately adjacent to one another on human
chromosome 6, and both cytokines are produced by Th17 cells in
response to IL-23 [8,9]. Several studies have found overexpressing
of IL-17A in various tumor tissues, including multiple myeloma,
ovarian cancers, gastric cancer and breast cancer [10–13].
Kawaguchi et al have shown that the IL-17F 7488T/C
(rs763780) variant, which causes a His-to-Arg substitution at amino
acid 161(H161R), antagonizes the function of wild-type IL-17Fand
influences the risk of asthma [14]. Polymorphisms in IL-17A
(rs2275913) and IL-17F (rs763780) have recently been identified to
be associated with the susceptibility to rheumatoid arthritis, gastric
cancer and ulcerative colitis, respectively [15–17]. However, it
remains unknown whether genetic polymorphisms in IL-17A and
IL-17F influence the risk of breast cancer development.
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e34400To investigate the role of the inflammatory cytokines IL-17A
and IL-17F in the pathogenesis of breast cancer, we selected
tagged single-nucleotide polymorphisms (SNPs) in the IL-17A and
IL-17F genes with Haploview software and then evaluated the
genotypes of these SNPs in breast cancer patients and controls
from the Chinese Han population. We also determined the
relationship between the polymorphisms in the IL-17A and IL-17F
genes and several prognostic factors, including tumor protein 53
(P53), estrogen receptor (ER), progesterone receptor (PR), human
epidermal growth factor receptor-2 (Her-2) and triple-negative
breast cancer (TNBC) in breast cancer patients.
Results
Genotypic and allelic frequencies
The genotypic and allelic frequencies of the IL-17A and IL-17F
polymorphisms in breast cancer patients and healthy controls are
shown in Table 1 and Table 2. All eight of the SNPs genotyped
were in Hardy-Weinberg equilibrium (HWE) (P.0.05) in our case
and control cohorts. Only the frequencies of the AA genotype and
the A allele in rs2275913, located at position 2197 from the
starting codon of the IL-17A gene, were statistical significant
higher in breast cancer patients than in controls (P=0.0016 and
P=0.0029, respectively). After highly conservative correction for
multiple testing, a significant association was also observed for the
A allele of rs2275913 (P=0.0311). The other seven SNPs
(rs3819025 and rs3748067 in the IL-17A gene and rs7771511,
rs9382084, rs12203582, rs1266828 and rs763780 in the IL-17F
gene) showed no significant differences in genotypic distribution
between the cases and the controls (P.0.05).
Haplotypes analysis
The associations of IL-17A and IL-17F SNPs with breast cancer
werefurtheranalyzedwiththeHaploviewprogram.Twoblockswere
identified with the software as shown in Figure S1. In the IL-17A
block, the frequency of the haplotype Ars2275913Grs3819025Grs3748067
w a sh i g h e ri np a t i e n t st h a ni nc o n t r o l s( P=0.0045), whereas the
frequency of the haplotype Grs2275913Grs3819025Grs3748067 was lower
(P=0 . 0 2 8 5 )i np a t i e n t st h a ni nc o n t r o l s .H o w e v e r ,a f t e rt h eP-value
was corrected for multiple testing using the permutation option in the
Haploview software, a significant association was only found for
haplotype Ars2275913Grs3819025Grs3748067 (P=0.0471). In the IL-17F
block, we did not find any haplotypes that were associated with breast
cancer (Table 3).
Clinical features
We analyzed the associations between the polymorphisms in the
IL-17A and IL-17F genes and a series of clinicopathologic
features, including clinical stage, lymph node metastasis, tumor
size, and the statuses of P53, ER, PR, Her-2 and TNBC. We
Table 1. Genotypes of eight SNPs in the IL-17A and IL-17F genes.
Reference SNP ID Genotype Frequency no. (%) P value Odds ratio (95% CI)
Patients (n=491) Controls (n=502)
rs2275913
{ G/G 165 (33.60) 198 (39.52) 0.1973
A/G 234 (47.66) 245 (48.90) 0.6950
A/A 92 (18.74) 58 (11.58) 0.0016 1.76 (1.24–2.51)
rs3819025
{ G/G 342 (69.65) 344 (68.66) 0.7354
A/G 132 (26.88) 145 (28.94) 0.4700
A/A 17 (3.46) 12 (2.40) 0.3185
rs3748067
{ G/G 336 (68.43) 332 (66.53) 0.5237
A/G 133 (27.09) 142 (28.46) 0.6306
A/A 22 (4.48) 25 (5.01) 0.6953
rs763780 T/T 382 (77.80) 396 (78.89) 0.6784
C/T 103 (20.98) 99 (19.72) 0.6229
C/C 6 (1.22) 7 (1.39) 0.8111
rs7771511 C/C 385 (78.41) 396 (78.88) 0.8556
C/T 100 (20.37) 100 (19.92) 0.8608
T/T 6 (1.22) 6 (1.20) 0.9692
rs12203582
{ G/G 201 (40.94) 226 (45.11) 0.7555
A/G 223 (45.42) 210 (41.92) 0.2663
A/A 67 (13.65) 65 (12.97) 0.1845
rs9382084 T/T 209 (42.57) 207 (41.24) 0.1673
G/T 226 (46.03) 223 (44.42) 0.6111
G/G 56 (11.41) 72 (14.34) 0.6708
rs1266828 T/T 341 (69.45) 345 (68.73) 0.9492
C/T 134 (27.29) 141 (28.09) 0.7589
C/C 16 (3.26) 16 (3.19) 0.8048
{controls=501, missing=1;
{controls=499, missing=3.
doi:10.1371/journal.pone.0034400.t001
IL-17 Gene Polymorphisms on Breast Cancer
PLoS ONE | www.plosone.org 2 March 2012 | Volume 7 | Issue 3 | e34400found no significant associations between IL-17A and IL-17F
SNPs and clinical stage, lymph node metastasis or ER status
(P.0.05).
As shown in Table 4, the frequency of genotype GG in
rs2275913 was higher in P53-positive cases (P=0.0302),
whereas the frequency of the G allele in rs3748067 was lower
(P=0.0357) in P53-positive cases. The polymorphisms in
rs2275913, rs3748067 and rs9382084 showed statistical differ-
ences in PR status (P,0.05). The frequencies of genotype AA in
rs2275913 (P=0.0350) and genotype GG in rs3748067
(P=0.0312) were lower in PR-positive cases, whereas the
frequencies of genotype AG in rs3748067 (P=0.0146) and
genotype GG in rs9382084 (P=0.0295) were higher in PR-
positive cases. The frequency of genotype AG in rs3819025 was
higher (P=0.0236) and the frequency of genotype AA in
rs12203582 was lower (P=0.0258) in Her-2-positive cases.
Finally, our findings indicated that the frequency of genotype
AA in rs3748067 was higher (P=0.0243) in patients with
TNBC, and the frequency of the G allele was higher in patients
with tumors=2 cm (P,0.0001).
We also analyzed the associations between each haplotypes and
the clinical features of the cases as predictive factors. Haplotype
Grs2275913Grs3819025Ars3748067 of IL-17A had a lower frequency in
P53-positive cases (P=0.0275), and haplotype Trs763780Crs7771511
Grs12203582Grs9382084Trs1266828 of IL-17F had a lower frequency in
PR-positive cases (P=0.0289) (Table 5).
Table 2. Allele frequencies of eight SNPs in the IL-17A and IL-17F genes.
Reference SNP ID Allele Frequency no. (%) P value Odds ratio (95% CI)
Patients (n=491) Controls (n=502)
rs2275913
{ A 418 (42.57) 361 (36.03) 0.0029
a 1.32 (1.10–1.58)
A/G G 564 (57.43) 641 (63.97)
rs3819025
{ G 816 (83.10) 833 (83.13) 0.9820
A/G A 166 (16.90) 169 (16.87)
rs3748067
{ G 805 (81.98) 806 (80.76) 0.4879
A/G A 177 (18.02) 192 (19.24)
rs763780 T 867 (88.29) 891 (88.75) 0.7500
C/T C 115 (11.71) 113 (11.25)
rs7771511 C 870 (88.59) 892 (88.85) 0.8603
C/T T 112 (11.41) 112 (11.15)
rs12203582
{ G 625 (63.65) 662 (66.07) 0.2585
A/G A 357 (36.35) 340 (33.93)
rs9382084 T 644 (65.58) 637 (63.45) 0.3203
G/T G 338 (34.42) 367 (36.55)
rs1266828 T 816 (83.10) 831 (82.77) 0.8465
C/T C 166 (16.90) 173 (17.23)
{controls=501, missing=1;
{controls=499, missing=3.
aP=0.0311 after correcting the P-value for multiple testing with the Haploview program using 10,000 permutations.
doi:10.1371/journal.pone.0034400.t002
Table 3. Haplotype frequencies in breast cancer patients and healthy controls.
Block Haplotype Freq. Breast Cancer (n=491) Healthy Controls (n=502) P value
IL-17A AGG 0.391 0.422 0.360 0.0045
a
GGG 0.254 0.232 0.275 0.0285
GGA 0.184 0.173 0.195 0.2051
GAG 0.167 0.165 0.169 0.8338
IL-17F TCATT 0.349 0.362 0.337 0.2383
TCGGT 0.185 0.176 0.194 0.2991
TCGTT 0.181 0.178 0.184 0.7103
TCGGC 0.171 0.168 0.173 0.7997
CTGTT 0.113 0.114 0.111 0.8049
The haplotypes contain the following SNPs in the order listed: IL-17A: rs2275913, rs3819025 and rs3748067; IL-17F: rs763780, rs7771511, rs12203582, rs9382084 and
rs1266828. The haplotypes occurred with a frequency of=10% in the case-control population.
aP=0.0471 after correcting the P-value for multiple testing with the Haploview program using 10,000 permutations.
doi:10.1371/journal.pone.0034400.t003
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Numerous data have shown that chronic inflammation is
associated with breast cancer [18,19]. Th17 cells mediate chronic
inflammation [3] and cancer [5,20]. IL-17A and IL-17F cytokines
are both expressed by Th17 cells, and they play a role in
coordinating local tissue inflammation by inducing the release of
proinflammatory and neutrophil-mobilizing cytokines. Although
the significance of IL-17A and IL-17F in the pathogenesis of breast
cancer is unclear, we hypothesized that both cytokines may affect
the development of breast cancer, either coordinately or
independently. Therefore, we investigated the influence of the
polymorphisms in these two cytokines in the pathogenesis of breast
cancer.
To date, no studies have investigated the association between
IL-17 gene polymorphisms and human breast cancer. In our case-
control study, for the first time we investigated the associations
between eight SNPs in the IL-17A (rs2275913, rs3819025 and
rs3748067) and IL-17F (rs763780, rs7771511, rs12203582,
rs9382084 and rs1266828) genes and the risk of sporadic breast
cancer in Chinese Han women. Genotyping of the eight SNPs in
our study showed that only rs2275913, located at position 2197
from the starting codon of the IL-17A gene, was correlated with
the risk of breast cancer. The homozygous AA genotype and the A
allele were more frequent in breast cancer patients. In the IL-17A
block, the frequency of haplotype Ars2275913Grs3819025Grs3748067
was higher in patients than in the controls. The other seven SNPs
showed no statistical significant differences in genotypic distribu-
tion between breast cancer cases and the controls. Therefore, our
investigation suggests that IL-17A, but not IL-17F, contributes to
breast cancer susceptibility, and the Chinese women with these
risk factors in the IL-17A gene may have an increased
susceptibility to breast cancers.
From the analysis of clinical information in conjunction with IL-
17A or IL-17F gene polymorphisms, we found that the IL-17A
and IL-17F genes may influence the diagnosis, treatment, and
prognosis of breast cancer. In the P53 analysis, we found that the
frequency of the rs2275913 GG genotype was higher and the
frequency of the rs3748067 G allele was lower in P53-positive
cases. The suppressor gene P53 is important in the treatment and
prognosis of breast cancer and the mutations in P53 can lead to
tumor metastasis and poor prognosis [21]. Both of these two SNPs
are located in the IL-17A gene, which indicates that IL-17A
polymorphisms are associated with P53 status and the occurrence
and progression of breast cancer.
The frequencies of the rs2275913 AA and rs3748067 GG
genotypes in IL-17A were lower in PR-positive patients, whereas
the frequency of the rs9382084 GG genotype in IL-17F was higher
in PR-positive patients. These SNPs in IL-17A and IL-17F were
significantly associated with PR status. Steroid hormone receptors
influence the disease-free and overall survival of breast cancer
patients and are considered to be predictive markers of endocrine
therapy [22,23]. Thus, the rs2275913 AA and rs3748067 GG
genotypes may be factors of poor prognosis and ineffective
treatment, whereas the rs9382084 GG genotype may be a good
marker of breast cancer. We also found that the frequencies of
rs3819025 AG in IL-17A and rs12203582 AA in IL-17F were
lower in Her-2-positive patients than in Her-2-negative patients.
Hormone and Her-2 receptors are two important pharmaceutical
targets that affect the survival of patients with metastatic breast
cancer [24]. In addition, the humanized antibody targeting Her-2
(Trastuzumab) is used in combination with chemotherapy to treat
patients with breast cancers overexpressing Her-2. These data
indicate that patients with the rs3819025 AG genotype or the
rs12203582 AA genotype may be insensitive to Trastuzumab.
According to these results, the variants of IL-17A and IL-17F may
Table 4. Clinical features associated with IL-17A and IL-17F gene polymorphisms.
Clinical feature Allele and genotype of SNP Frequency no. (%) P value Odds ratio (95% CI)
Positive Negative
P53 rs2275913 GG 41 (41.84) 101 (30.15) 0.0302 0.60 (0.38–0.95)
rs3748067 G 150 (76.53) 557 (83.13) 0.0357 0.66 (0.45–0.97)
PR rs2275913 AA 35 (2.86) 45 (22.61) 0.0350 1.69 (1.04–2.74)
rs3748067 AG 76 (32.07) 43 (21.61) 0.0146 0.58 (0.38–0.90)
rs3748067 GG 151 (63.71) 146 (73.37) 0.0312 1.57 (1.04–2.36)
rs9382084 GG 35 (14.77) 16 (8.04) 0.0295 0.50 (0.93–0.27)
Her-2 rs3819025 AG 42 (34.71) 75 (23.96) 0.0236 0.59 (0.38–0.93)
rs12203582 AA 10 (8.26) 52 (16.61) 0.0258 2.21 (1.10–4.44)
TNBC rs3748067 AA 7 (9.59) 15 (3.59) 0.0243 2.85 (1.16–6.99)
doi:10.1371/journal.pone.0034400.t004
Table 5. Clinical features associated with haplotypes.
Clinical feature Block Haplotype Freq. Positive Negative P value
P53 IL-17A GGA 0.175 0.159 0.227 0.0275
PR IL-17F TCGGT 0.175 0.144 0.200 0.0289
The haplotypes contain the following SNPs in the order listed: IL-17A: rs2275913, rs3819025 and rs3748067; IL-17F: rs763780, rs7771511, rs12203582, rs9382084 and
rs1266828. The haplotypes shown occurred with a frequency of=10% in the case-control population.
doi:10.1371/journal.pone.0034400.t005
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effectiveness of pharmaceuticals treatments.
Furthermore, our findings also indicated that the frequency of
the rs3748067 AA genotype in the 39UTR of IL-17A was higher in
patients with TNBC, which suggested that patients homozygous
for AA in rs3748067 may have a poor prognosis. TNBC is defined
by the absence of ER, PR and Her-2 expression, as assessed
through immunohistochemical analysis. Because they lack these
common therapeutic targets, patients with TNBC have a worse
prognosis and tends to relapse early compared with patients with
other subtypes of breast cancer [25]. The 39UTR can regulate
gene expression at different levels and mediate the stability,
degradation, and subcellular localization of mRNA [26]. Addi-
tionally, we found that the frequency of the G allele of rs3748067
was higher in patients with tumors=2 cm. Therefore, the
polymorphism in rs3748067 may change the IL-17A expression
and further affect the prognosis of breast cancer patients.
Finally, the results of our haplotype analysis demonstrated that
the haplotype Grs2275913Grs3819025Ars3748067 of IL-17A and the
haplotype Trs763780Crs7771511Grs12203582Grs9382084Trs1266828 of IL-
17F were less frequent in patients with P53- and PR-positive
statuses, respectively. Therefore, haplotype Grs2275913Grs3819025
Ars3748067 may be a marker of good prognosis, whereas haplotype
Trs763780Crs7771511Grs12203582Grs9382084Trs1266828 may be a marker
of poor prognosis for breast cancer patients.
In conclusion, our study determined the relationships between
IL-17A and IL-17F gene polymorphisms and the risk of breast
cancer in Chinese women. These results suggested that SNPs in
IL-17A but not IL-17F had a significant association with breast
cancer risk. Both IL-17A and IL-17F gene polymorphisms may
provide valuable information for predicting the prognosis and
effectiveness of pharmaceutical treatment in Chinese breast cancer
patients.
Materials and Methods
Subjects
Our study included 491 Chinese women with breast cancer but
no family history of cancer and 502 healthy women. The sporadic
breast cancer patients were selected from the Department of
Breast Surgery (The Third Affiliated Hospital of Harbin Medical
University, Heilongjiang Province) and ranged in age from 27 to
91 years old (mean age 49.5610.3 years). The breast cancer
patients were diagnosed based on surgical and pathological
symptoms. The control group consisted of 502 age-matched
healthy Han women (mean age 49.069.9 years) who were
volunteers in the same district and had no history of tumors or
inflammatory diseases. And imaging examinations were done for
the volunteers to rule out breast cancer. Both the breast cancer
group and the healthy control group were from the Heilongjiang
Province of China and all of the blood samples were obtained from
September 2008 to May 2009. The Ethics Committee of Harbin
Medical University approved the study protocol, and written
informed consent was obtained from all of the participating
subjects.
Clinicopathological evaluation
The clinicopathologic information of breast cancer patients was
shown in Table 6. We retrospectively evaluated conventional
clinicopathological factors and the immunohistochemistry (IHC)
results for four biological factors (ER, ZM0104; PR, ZM0215;
Her-2, ZM0065; P53, ZA-0501; Beijing ZhongShan Golden-
Bridge Biological Technology CO., LTD, China) using paraffin
embedded tissues according to the reported recommendations for
Table 6. Clinicopathologic description of the breast cancer
patients (n=491).
Clinicopathologic information Case no. (%)
Histology
Infiltrative ductal carcinoma 420 (85.54)
Intraductal carcinoma 36 (7.33)
Mucinous adenocarcinoma 13 (2.65)
Infiltrative lobular carcinoma 12 (2.44)
Medullary carcinoma 4 (0.81)
Others 6 (1.22)
Clinical Stage (UICC)
0 2 (0.41)
I 124 (25.25)
II 256 (52.14)
III 37 (7.54)
IV 8 (1.63)
Unknown 64 (13.03)
Tumor size (cm)
TZ=2 236 (48.07)
2,TZ=5 223 (45.42)
TZ.5 28 (5.70)
Unknown 4 (0.81)
LN involvement
Positive 204 (41.55)
Negative 261 (53.15)
Unknown 26 (5.30)
P53
Positive 98 (19.96)
Negative 335 (68.23)
Unknown 58 (11.81)
ER
Positive 266 (54.18)
Negative 169 (34.42)
Unknown 56 (11.40)
PR
Positive 237 (48.27)
Negative 199 (40.53)
Unknown 55 (11.20)
Her-2
Positive 121 (24.64)
Negative 313 (63.75)
Unknown 57 (11.61)
IHC subtype
ER or PR(+)/Her-2(2) 240 (48.88)
ER or PR(+)/Her-2(+) 52 (10.59)
ER(2)/PR(2)/Her-2(2) 73 (14.87)
ER(2)/PR(2)/Her-2(+) 69 (14.05)
Unknown 57 (11.61)
Abbreviations:
LN, lymph node; P53, tumor protein 53; ER, estrogen receptor; PR, progesterone
receptor; TZ, tumor size; Her-2, human epidermal growth factor receptor-2; IHC,
immunohistochemistry.
doi:10.1371/journal.pone.0034400.t006
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clinical stage was assessed according to the criteria described in the
International Union Against Cancer (UICC).
A cut-off value of 10% of positively stained nuclei was used to
define ER and PR positivity; Her-2 was scored as 0–3+ according
to membrane staining. Cases with IHC scores of 3+ or 2+ with
gene amplification by fluorescence in situ hybridization (FISH)
were considered positive for Her-2. Cells with positive staining for
P53 were counted and expressed as a percentage. We scored the
immunostained slides as 0–3+ (0, negative; 1+, =25%; 2+, 25–
50%; 3+, .50%). For the prognosis comparison, low expression
was defined as P53=25% (median values for all evaluated
tumors).
DNA extraction
Genomic DNA was isolated from EDTA anti-coagulated whole
blood using the AxyPrep Blood Genomic DNA Miniprep Kit
(Axygen Biotechnology, USA). Each DNA sample was stored at
220uC until analysis.
SNP selection and genotyping
SNP selection performed with Haploview v4.0 through pairwise
tagging (r
2.0.80) and minor allele frequencies .0.1 using Chinese
(CHB) genotype data from HapMap (http://www.hapmap.org/)
covering the IL-17A and IL-17F genes. Two SNPs (rs3819025 and
rs3748067) of the IL-17A gene and four SNPs (rs7771511,
rs9382084, rs12203582 and rs1266828) of the IL-17F gene were
selected as tags. The SNP rs2275913 in the IL-17A gene promoter
and the non-synonymous coding SNP rs763780 (p.His161Arg) in
the IL-17F gene were also selected because they are associated
with some cancers.
The SNaPshot SNP assay was performed to detect the
dimorphism at the eight SNP loci. The PCR primer pairs used
to amplify the DNA sequences are shown in Table S1. PCR was
performed in a 20 ml reaction mixture containing 1 ml (10 ng) of
template DNA, 1 mM of each primer, 0.3 mM of each
deoxynucleotide triphosphate, 3.0 mM of MgCl2, and 1 U
HotStarTaq polymerase (Qiagen Inc., USA) with 16HotStarTaq
buffer. The PCR program was consisted of an initial melting step
of 15 minutes at 95uC; 11 cycles of 20 seconds at 94uC,
40 seconds at 65uC-0.5uC/cycle, and 90 seconds at 72uC; 24
cycles of 20 seconds at 94uC, 30 seconds at 59uC, and 90 seconds
at 72uC; and a final elongation step of 2 minutes at 72uC. To
purify the PCR products, 1 U SAP and 1 U Exonuclease I were
mixed with 10 ml PCR product for 1 hour at 37uC and 15 minutes
at 75uC. The SNaPshot multiplex single-base extension reaction
primer sequences are shown in Table S1. The extension reaction
was performed in a 10 ml reaction mixture containing 5 ml of the
SNaPshot Multiplex Kit (Applied Biosystems, USA), 2 mlo f
purified PCR products, 0.8 mM of the extension reaction primer,
and 2 ml water. The PCR program was consisted of 1 minute at
96uC; 28 cycles of 10 seconds at 96uC, 5 seconds at 50uC, and
30 seconds at 60uC; and 4uC as the holding temperature. Finally,
10 ml of the extension product was purified with 1 U SAP for
1 hour at 37uC and inactivated for 15 minutes at 75uC.
The resulting data were analyzed with an ABI3130XL
sequencer and GeneMapper
TM 4.0 Software (Applied Biosystems,
Co. Ltd., USA). The SNP genotyping figure is shown in Table S2.
To ensure quality control (QC), genotyping was performed by
researchers blinded to the case/control status of the subjects, and a
random sample of 5% of the cases and controls was genotyped
twice by different persons, with a reproducibility of 100%.
Statistical analysis
The genotypes in both data sets were in HWE. The frequencies
of alleles and genotypes were obtained through direct counting.
The statistical significance was defined as P,0.05. We used
Haploview software to construct haplotypes and estimate haplo-
type frequencies for both cases and controls. Only the haplotypes
that occurred at a frequency of=10% in the case-control
population were selected in our study. To obtain a measure of
significance that was corrected for multiple testing bias, we ran
10,000 permutations to compute P-values using the Haploview
program. The comparisons of the distributions of the genotype,
allele and haplotype frequencies were performed using the Chi-
square test. The relative risk associated with rare alleles, genotypes
and haplotypes was estimated as an odds ratio (OR) with a 95%
confidence interval (CI).
Supporting Information
Figure S1 Linkage disequilibrium (LD) block defined
with the Haploview program based on the solid spine of
LD method. Pairwise LD coefficients D96100 are shown
in each cell. The standard color scheme was applied for the LD
color display.
(TIF)
Table S1 Product size and primer sequences of eight
SNPs in the IL-17A and IL-17F genes.
(DOC)
Table S2 SNP genotyping figure.
(PDF)
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